Evidence map›Paper›PMID 21541358›Full record

ArticlePLoS neglected tropical diseases2011

HTLV-1 tax specific CD8+ T cells express low levels of Tim-3 in HTLV-1 infection: implications for progression to neurological complications.

Lishomwa C Ndhlovu, Fabio E Leal, Aaron M Hasenkrug, Aashish R Jha, Karina I Carvalho, Ijeoma G Eccles-James, Fernanda R Bruno, Raphaella G S Vieira, Vanessa A York, Glen M Chew and 8 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Clinical Significance of T-Cell Immunoglobulin Mucin 3 Expression on Peripheral Blood Mononuclear Cells in Pediatric Acute Immune Thrombocytopenia.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis · 2018
    Article
  7. Review
  8. HTLV-1 Infection and Neuropathogenesis in the Context of Rag1Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2017
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 5 countries.

Lishomwa C NdhlovuDivision of Experimental Medicine, Department of Medicine, University of California San Francisco, San Francisco, California, United States of America. lndhlovu@medsfgh.ucsf.edu
Fabio E Leal
Aaron M Hasenkrug
Aashish R Jha
Karina I Carvalho
Ijeoma G Eccles-James
Fernanda R Bruno
Raphaella G S Vieira
Vanessa A York
Glen M Chew
R Brad Jones
Yuetsu Tanaka
Walter K Neto
Sabri S Sanabani
Mario A Ostrowski
Aluisio C Segurado
Douglas F Nixon
Esper G Kallas
University of California, San Francisco · USMicrosoft (Brazil) · BRFundação Pró-Sangue Hemocentro de São Paulo · BRToronto Public Health · CAUniversidade de São Paulo · BRUniversity of the Ryukyus · JPUniversity of Toronto · CA

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Monica Gandhi · 1988 to 2026
$93.6M
University of California, Berkeley (UCB)/University of *D43TW000003 · FIC · UNIVERSITY OF CALIFORNIA BERKELEY · PI REINGOLD, ARTHUR L · 1988 to 2013
$16.7M
THE EMERGENCE OF HIV GENETIC DIVERSITY IN CAMEROONK01TW000003 · FIC · JOHNS HOPKINS UNIVERSITY · PI WOLFE, NATHAN D · 1999 to 2005
$634k
Modulating Tim-3 to control HIV infectionR56AI083112 · NIAID · UNIVERSITY OF HAWAII AT MANOA · PI NDHLOVU, LISHOMWA C · 2010 to 2010
$377k
SPECIAL INTERNATIONAL POSTDOCTORAL RESEARCH PROGRAMT22TW000003 · FIC · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI FAHEY, JOHN L. · 1988 to 1999
–
FIC NIH HHS D43 TW000003FIC NIH HHS D43 TW00003FIC NIH HHS K01 TW000003FIC NIH HHS T22 TW000003NIAID NIH HHS P30 AI027763NIAID NIH HHS R56 AI083112NIAID NIH HHS R56AI083112
6 · The paper itself

Abstract

The T cell immunoglobulin mucin 3 (Tim-3) receptor is highly expressed on HIV-1-specific T cells, rendering them partially "exhausted" and unable to contribute to the effective immune mediated control of viral replication. To elucidate novel mechanisms contributing to the HTLV-1 neurological complex and its classic neurological presentation called HAM/TSP (HTLV-1 associated myelopathy/tropical spastic paraparesis), we investigated the expression of the Tim-3 receptor on CD8(+) T cells from a cohort of HTLV-1 seropositive asymptomatic and symptomatic patients. Patients diagnosed with HAM/TSP down-regulated Tim-3 expression on both CD8(+) and CD4(+) T cells compared to asymptomatic patients and HTLV-1 seronegative controls. HTLV-1 Tax-specific, HLA-A*02 restricted CD8(+) T cells among HAM/TSP individuals expressed markedly lower levels of Tim-3. We observed Tax expressing cells in both Tim-3(+) and Tim-3(-) fractions. Taken together, these data indicate that there is a systematic downregulation of Tim-3 levels on T cells in HTLV-1 infection, sustaining a profoundly highly active population of potentially pathogenic T cells that may allow for the development of HTLV-1 complications.

Indexed as

Gene Expression ProfilingAdultAgedCD8-Positive T-LymphocytesFemaleGene Products, taxHepatitis A Virus Cellular Receptor 2HumansHuman T-lymphotropic virus 1MaleMembrane ProteinsMiddle AgedParaparesis, Tropical SpasticGene Products, taxHAVCR2 protein, humanHepatitis A Virus Cellular Receptor 2Membrane Proteinstax protein, Human T-lymphotrophic virus 1

Identifiers

PMID21541358
PMCPMC3082508
OpenAlexW2083710909

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.